Sign in
Taking people in South KoreaPhase 2

Long-term safety of ONO-4538 in people with various cancers

Checks long-term safety of ONO-4538 in people with cancer continuing prior treatment.

Key facts

Who runs it
Ono Pharmaceutical Co., Ltd.
Where
Daegu, Gyeonggi-do, Hwasun, Incheon, Seoul, and Suwon, South KoreaSee the 13 sitesAlso in 2 other countries, 31 sites
Trial code
Registry title
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Status
Recruiting
Phase
Phase 2
People taking part
70 people, planned
Started
10 Sept 2020
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groups
Treatments tested
  • ONO-4538
  • oxaliplatin
  • S-1
  • capecitabine
  • bevacizumab
  • temozolomide
  • Ipilimumab
  • ONO-7703
Record updated
14 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with cancer who are already being treated with ONO-4538, alone or with other therapies, in another clinical trial and are continuing that treatment.

Age
16 years or older
Sex
All sexes can join
Disease stage
Any tumor type (pan-tumor); the person must be getting ONO-4538 in a clinical trial.
Earlier treatment
Must currently be treated with ONO-4538, alone or with other therapies, in a clinical trial.

Main reasons for not taking part

  • Cannot give consent, for example because of dementia
  • The investigator judges the person inappropriate for this study

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials
  • Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or investigator-assessed clinical benefit

Who cannot take part

  • Participant judged to be incapable of providing consent for reasons such as concurrent dementia
  • Participant judged by the investigator to be inappropriate as participants of this study

Where in South Korea

Also in 2 other countries, 31 sites

  • DaeguHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
  • Daegu, South KoreaHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
  • DaeguHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
  • Gyeonggi-doHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
  • HwasunHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
  • IncheonHospital not named in the registryContact: North America Clinical Trial Support DeskNo longer taking part
  • SeoulHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
  • SeoulHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
  • SeoulHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
  • SeoulHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
  • SeoulHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
  • SeoulHospital not named in the registryContact: North America Clinical Trial Support DeskNo longer taking part
  • SuwonHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people

About the trial

What the trial wants to find out

This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.

The 2 groups in the trial

  • ONO-4538 Monotherapy cohortTreatment being tested

    480 mg of ONO-4538 IV Q4W or 240 mg of ONO-4538 IV Q2W per the investigator's choice

    Treatment: ONO-4538

  • Combination therapy cohortTreatment being tested

    ONO-4538 at 360 mg IV Q3W or 480 mg IV Q4W, and Combination therapies (S-1 + Oxaliplatin \[SOX\] therapy , Capecitabine + Oxaliplatin \[CapeOX\] therapy , Bevacizumab, Temozolomide, Ipilimumab + SOX therapy, Ipilimumab + CapeOX therapy or ONO-7703) selected by the principal investigator or subinvestigator in the Parent Study will be continued in this study.

    Treatment: ONO-4538, oxaliplatin, S-1, capecitabine, bevacizumab, temozolomide, Ipilimumab, and ONO-7703

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Open-label, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 as Monotherapy or in Combination With Other Therapies and Are Continuing ONO-4538 Treatment (ONO-4538-98)
Plain-language title
Long-term safety of ONO-4538 in people with various cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
14 October 2026